CompanyAVLNNasdaqBoston, MA

Avalyn Pharma Inc.

Avalyn develops inhaled formulations of antifibrotic medicines for pulmonary fibrosis.

SEC EDGAR ClinicalTrials.gov avalynpharma.com

8-KSep 16Latest SEC filing, period to Sep 15

Sep 16Latest story

September 2026

Avalyn Pharma adds Robert Meyer, M.D. to board of directors

Sep 16PeopleAvalyn Pharma Inc.

August 2026

Avalyn completes enrollment in Phase 2b pulmonary fibrosis trial of AP01

Aug 12Quarterly updateAvalyn Pharma Inc.pirfenidone solution

July 2026

Avalyn Pharma expands Boston sublease with CRISPR Therapeutics

Jul 1PartnershipAvalyn Pharma Inc.